Alcon’s Triesence receives FDA approval for eye surgery

Switzerland-based eye-care company Alcon has said that the FDA has approved Triesence injectable suspension 40mg/mL, a preservative-free synthetic corticosteroid for visualization, during vitrectomy and treatment of sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids.